A Retrospective Observational Study to Evaluate the Utilization, Outcomes, and Adverse Events in Participants Treated With Minocin® (Minocycline) for Infections Caused by Gram-negative Bacteria in a Real World Setting

This study is a retrospective, observational study to evaluate minocycline use in
participants under real world conditions.

Inclusion Criteria:

- The participant was treated with Minocin IV for a presumed or culture-confirmed
gram-negative infection, as monotherapy or part of a broader regimen, for at least 48
hours.

- The participant treatment for gram-negative infection was initiated May 1, 2015, or
later.

- The participant was at least 18 years old.

- This was the first course of Minocin IV administered to the participant within the
study period for the treatment of gram-negative infection.

- At least 60 days has elapsed since the participant received the last dose of Minocin
IV therapy for a presumed or confirmed gram-negative infection (prior to data entry
into the electronic case report form, including step-down to oral therapy.

Exclusion Criteria:

- The participant received Minocin IV as a part of a controlled clinical trial.

- The participant received Minocin IV as a part of a Medicines Company- or Rempex
Company-sponsored pharmacoeconomic outcomes study.

- Pregnancy (in the participant's or participant's partner) occurred after the first
dose of Minocin IV through hospital discharge.

- Female participants were pregnant or nursing at the time of enrollment.